Logo

BIO-B

Bio-Rad Laboratories, Inc.

BIO-B

Bio-Rad Laboratories, Inc. • NYSE
$310.70 ▲ 0.00% (+0.00)
Market Cap $8.38 B
52w High $359.22
52w Low $225.29
Dividend Yield 0%
P/E -12.94
Volume 17
Outstanding Shares 26.97M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $653M ▲ $278.1M ▲ $-341.9M ▼ -52.358% ▼ $-12.7 ▼ $-384.6M ▼
Q2-2025 $651.6M ▲ $268.2M ▼ $317.8M ▲ 48.772% ▲ $11.67 ▲ $477.2M ▲
Q1-2025 $585.4M ▼ $282.3M ▼ $64M ▲ 10.933% ▲ $2.29 ▲ $133.5M ▲
Q4-2024 $667.475M ▲ $283.582M ▼ $-715.8M ▼ -107.24% ▼ $-25.57 ▼ $-847.4M ▼
Q3-2024 $649.729M $291.437M $653.172M 100.53% $23.37 $922.894M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.421B ▲ $9.696B ▼ $2.96B ▼ $6.737B ▼
Q2-2025 $1.374B ▼ $10.214B ▲ $3.085B ▲ $7.129B ▲
Q1-2025 $1.66B ▼ $9.527B ▲ $2.848B ▲ $6.679B ▲
Q4-2024 $1.665B ▲ $9.364B ▼ $2.795B ▼ $6.569B ▼
Q3-2024 $1.622B $10.603B $3.116B $7.488B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-341.9M ▼ $120.9M ▲ $-43M ▲ $-52.5M ▲ $26.5M ▲ $89.2M ▲
Q2-2025 $-120.1M ▼ $116.5M ▼ $-115.4M ▼ $-136.3M ▼ $-151.4M ▼ $70.8M ▼
Q1-2025 $64M ▲ $129.9M ▲ $2.9M ▲ $-97.7M ▼ $33.3M ▼ $95.5M ▲
Q4-2024 $-715.8M ▼ $124.152M ▼ $-30.544M ▲ $-26.248M ▲ $77.612M ▲ $81.248M ▼
Q3-2024 $653.2M $163.61M $-55.636M $-95.986M $4.473M $99.971M

Revenue by Products

Product Q3-2024Q4-2024Q2-2025Q3-2025
Clinical Diagnostics
Clinical Diagnostics
 $390.00M ▲$390.00M ▲$390.00M ▲$390.00M ▲
Life Science
Life Science
 $260.00M ▲$280.00M ▲$260.00M ▼$260.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Bio‑Rad’s revenue has been roughly flat to slightly down over the past few years, suggesting a mature business rather than a fast‑growing one. Core operations still generate a healthy gross profit and positive operating income, but reported earnings have been extremely volatile and recently negative. That pattern hints at sizable non-operating or accounting-driven items affecting profit, rather than a collapse in the underlying business. Overall, the income statement shows a solid but low‑growth franchise with noisy bottom‑line results that can swing sharply from year to year.

Balance Sheet

Balance Sheet The balance sheet shows a company with substantial assets and equity, but both have drifted down from earlier peak levels as recent losses have accumulated. Debt is meaningful but not overwhelming relative to the size of the business and equity base, and cash on hand is steady but not especially large. This points to a generally sound financial position, though with less of a cushion than a few years ago and some pressure from added leverage and declining book value.

Cash Flow

Cash Flow Despite weak reported earnings, Bio‑Rad continues to generate positive cash from its day‑to‑day operations, which is a key strength. Free cash flow is consistently positive, though not particularly large, and capital spending has been kept at a moderate, stable level. In practical terms, the company is still turning its business activity into cash and funding its investments internally, even as accounting earnings move up and down sharply.

Competitive Edge

Competitive Edge Bio‑Rad holds a strong, specialized position in life science research and clinical diagnostics rather than trying to be the broadest one‑stop shop. Its proprietary technologies, especially in droplet digital PCR, deep relationships with labs and hospitals, and global distribution give it meaningful staying power. High switching costs for installed instruments and reagents help keep customers loyal. Against much larger rivals, Bio‑Rad competes by owning specific niches where its tools are viewed as a standard, rather than by matching competitors product for product across the entire market.

Innovation and R&D

Innovation and R&D Innovation is a clear centerpiece of Bio‑Rad’s strategy. The company has built a leading position in droplet digital PCR and continues to extend that platform into areas like oncology, cell and gene therapy, and single‑cell analysis. It also invests in improving diagnostic controls, blood typing, and specialized reagents. The R&D focus is on high‑value, science‑driven applications where accuracy and sensitivity matter more than price, which can support premium positioning but also requires ongoing investment and careful execution.

Summary

Bio‑Rad looks like a technically strong, innovation‑driven lab tools and diagnostics company with steady, if unspectacular, revenue and a history of strong gross margins. The main financial concern is the disconnect between relatively stable operating performance and very volatile, recently negative reported earnings, which suggests complex non-core or accounting impacts. The balance sheet remains solid but has weakened from prior highs, while cash generation is still positive and supports continued innovation. Strategically, Bio‑Rad benefits from differentiated technology, sticky customer relationships, and focus on attractive niches, but it operates in a highly competitive industry and must continue to innovate and manage capital carefully to sustain its position.